Mereo BioPharma and Sentynl sign option deal for alvelestat in lung disease
Sentynl gets an option for U.S. rights to Mereo's alvelestat, with milestone payments up to $435 million if the option is exercised.
SEC filing
Latest
2 stories
Tuesday, August 11
Mereo BioPharma reports Q2 2026 results, alvelestat licensing deal with Sentynl
Mereo said cash of $30.1 million should fund operations into late-2027 as it advances option deals for alvelestat and continues regulatory talks on setrusumab.
SEC filing